Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.

Shi-Ming Tu

Concepts (117)

Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.

Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Testicular Neoplasms
18
2024
64
4.530
Why?
Neoplasms, Germ Cell and Embryonal
13
2024
36
3.280
Why?
Seminoma
4
2018
8
1.870
Why?
Prostatic Neoplasms
7
2021
393
0.940
Why?
Adenocarcinoma
5
2020
402
0.880
Why?
Drug Resistance, Neoplasm
3
2018
315
0.710
Why?
Neoplasms
3
2022
1233
0.670
Why?
Neoplastic Stem Cells
3
2016
100
0.630
Why?
Glypicans
1
2018
1
0.620
Why?
Neoplasm Metastasis
6
2022
235
0.610
Why?
Endodermal Sinus Tumor
2
2018
2
0.600
Why?
Tissue Extracts
1
2017
13
0.580
Why?
Up-Regulation
1
2018
446
0.540
Why?
Immunotherapy
1
2017
235
0.500
Why?
Male
29
2024
25572
0.490
Why?
CA-125 Antigen
1
2014
17
0.480
Why?
Neoplasm Recurrence, Local
6
2020
630
0.480
Why?
Retrospective Studies
12
2022
6190
0.440
Why?
Middle Aged
21
2024
12356
0.440
Why?
Radiopharmaceuticals
1
2014
205
0.420
Why?
Fluorodeoxyglucose F18
1
2014
190
0.410
Why?
Lymph Node Excision
7
2020
138
0.400
Why?
Positron-Emission Tomography
1
2014
288
0.400
Why?
Immunohistochemistry
6
2024
973
0.380
Why?
Carcinoma, Ductal
2
2021
9
0.360
Why?
Aged
12
2024
9505
0.360
Why?
Viscera
1
2010
23
0.360
Why?
Humans
31
2024
50201
0.360
Why?
Adult
18
2024
13486
0.340
Why?
Mutation
3
2022
1288
0.320
Why?
Tomography, X-Ray Computed
1
2014
1160
0.310
Why?
Neoplasm Grading
2
2020
123
0.290
Why?
Young Adult
8
2024
4052
0.280
Why?
Prostate-Specific Antigen
4
2020
47
0.280
Why?
Stem Cells
2
2022
171
0.260
Why?
Prognosis
6
2014
1963
0.250
Why?
Trophoblastic Neoplasms
1
2024
2
0.240
Why?
Epithelioid Cells
1
2024
13
0.240
Why?
Antineoplastic Combined Chemotherapy Protocols
4
2018
1000
0.240
Why?
Lymphatic Metastasis
5
2009
226
0.200
Why?
Neuroectodermal Tumors, Primitive, Peripheral
1
2022
2
0.200
Why?
Wilms Tumor
1
2022
18
0.200
Why?
Carcinoma
2
2022
139
0.200
Why?
Penile Neoplasms
1
2002
45
0.190
Why?
Adolescent
9
2022
6459
0.190
Why?
Sarcoma
1
2022
65
0.180
Why?
Carcinoembryonic Antigen
2
2014
14
0.170
Why?
Genetic Predisposition to Disease
1
2002
508
0.160
Why?
Survival Analysis
3
2017
670
0.160
Why?
Choriocarcinoma, Non-gestational
1
2018
2
0.150
Why?
Autopsy
1
2018
47
0.150
Why?
Chorionic Gonadotropin, beta Subunit, Human
2
2024
6
0.150
Why?
Teratoma
2
2009
26
0.150
Why?
Phenotype
2
2016
732
0.150
Why?
Salvage Therapy
1
2018
136
0.150
Why?
Exome
1
2016
46
0.140
Why?
Survival Rate
3
2014
906
0.140
Why?
Cisplatin
1
2018
275
0.130
Why?
Genetic Heterogeneity
1
2016
18
0.130
Why?
Disease Progression
5
2011
821
0.130
Why?
alpha-Fetoproteins
2
2013
15
0.130
Why?
Lung Neoplasms
2
2020
601
0.130
Why?
Randomized Controlled Trials as Topic
1
2018
553
0.120
Why?
Proportional Hazards Models
1
2016
408
0.120
Why?
Multivariate Analysis
1
2016
581
0.120
Why?
False Positive Reactions
1
2014
62
0.110
Why?
Gene Expression Regulation, Neoplastic
1
2018
824
0.110
Why?
Treatment Outcome
5
2024
5203
0.110
Why?
Chemoradiotherapy
1
2014
43
0.110
Why?
Postoperative Complications
1
2020
1027
0.110
Why?
Bone Morphogenetic Protein 2
1
2013
46
0.110
Why?
Cell Differentiation
1
2016
648
0.110
Why?
Neoplasm, Residual
1
2014
160
0.110
Why?
Glutathione Transferase
1
2013
173
0.100
Why?
Aged, 80 and over
2
2017
3158
0.100
Why?
Bone Neoplasms
2
2011
178
0.090
Why?
Receptors, Platelet-Derived Growth Factor
1
2011
6
0.090
Why?
Quinazolines
1
2011
32
0.090
Why?
Octamer Transcription Factor-3
1
2010
2
0.090
Why?
Sialoglycoproteins
1
2010
12
0.090
Why?
Antigens, Surface
1
2010
48
0.090
Why?
Proto-Oncogene Proteins c-kit
1
2010
36
0.090
Why?
Retroperitoneal Space
5
2007
32
0.090
Why?
Orchiectomy
3
2022
41
0.090
Why?
Proteoglycans
1
2010
81
0.090
Why?
Disease-Free Survival
5
2011
450
0.090
Why?
Hemangiosarcoma
1
2010
16
0.090
Why?
Piperazines
1
2011
118
0.090
Why?
Mediastinal Neoplasms
1
2010
19
0.090
Why?
Retroperitoneal Neoplasms
1
2009
20
0.080
Why?
Pilot Projects
1
2010
703
0.070
Why?
Proteins
1
2010
348
0.070
Why?
Antineoplastic Agents
2
2011
1176
0.060
Why?
Lymph Nodes
1
2006
258
0.060
Why?
Child
1
2016
6862
0.060
Why?
Neoplasm Invasiveness
1
2002
269
0.050
Why?
Combined Modality Therapy
3
2007
639
0.050
Why?
Hematologic Neoplasms
1
2002
99
0.050
Why?
Thorax
1
2020
16
0.040
Why?
Sensitivity and Specificity
1
2002
871
0.040
Why?
Prostatectomy
1
2020
82
0.040
Why?
Prostate
1
2020
117
0.040
Why?
Risk
2
2007
315
0.030
Why?
Risk Assessment
1
2020
1255
0.030
Why?
Neoplasm Staging
2
2009
749
0.030
Why?
Drug Administration Schedule
1
2011
369
0.020
Why?
Rhabdomyosarcoma
1
2010
12
0.020
Why?
Leiomyosarcoma
1
2010
23
0.020
Why?
Recurrence
1
2009
660
0.020
Why?
Forecasting
1
2007
145
0.020
Why?
Pathology, Surgical
1
2006
18
0.020
Why?
Syndrome
1
2007
239
0.020
Why?
Population Surveillance
1
2007
161
0.020
Why?
Brain Neoplasms
1
2007
286
0.010
Why?
Liver Neoplasms
1
2007
331
0.010
Why?
Time Factors
1
2009
2909
0.010
Why?
Female
1
2020
26829
0.010
Why?
Tu's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
_
Co-Authors Expand Description
_
Similar People Expand Description
_
Same Department Expand Description